A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

Critical Care

Volumn 16, Issue 1, 2012, Pages

  Morris, Peter E ^a   Zeno, Brian ^b   Bernard, Andrew C ^c   Huang, Xiangning ^d   Das, Shampa ^d   Edeki, Timi ^d   Simonson, Steven G ^e   Bernard, Gordon R ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b RIVERSIDE METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d ASTRAZENECA   (United Kingdom)

^e AGENNIX INC   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOFAB; DROTRECOGIN; INTERLEUKIN 6; PLACEBO; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN F(AB) FRAGMENT;

ABDOMINAL INFECTION; ACIDOSIS; ACUTE HEART INFARCTION; ADULT; AGITATION; ANEMIA; APACHE; AREA UNDER THE CURVE; ARTICLE; ASPIRATION PNEUMONIA; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CELLULITIS; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DECUBITUS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EMPYEMA; ENDOCARDITIS; ENTEROCUTANEOUS FISTULA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENERALIZED EDEMA; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMORRHAGIC SHOCK; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOXIA; INSOMNIA; INTESTINE ISCHEMIA; INTESTINE PERFORATION; INTRAOCULAR HEMORRHAGE; LOADING DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUSCLE BLEEDING; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL ISCHEMIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SCLERA DISEASE; SEPSIS; SEPTIC SHOCK; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; WHEEZING; AGED; ANIMAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SHEEP;

ADULT; AGED; ANIMALS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEPSIS; SEVERITY OF ILLNESS INDEX; SHEEP; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863404346     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11203     Document Type: Article

References (27)

1. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250. 10.1097/01.CCM.0000261890.41311.E9, 17414736.
2. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
3. Sharma VK, Dellinger RP. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther 2006, 4:395-403. 10.1586/14787210.4.3.395, 16771617.
4. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986, 163:1363-1375. 10.1084/jem.163.6.1363, 2188127, 3011946.
5. Spooner CE, Markowitz NP, Saravolatz LD. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopathol 1992, 62:S11-S17. 10.1016/0090-1229(92)90036-N, 1370262.
6. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999, 13:413-426. 10.1016/S0891-5520(05)70083-0, 10340175.
7. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med 1995, 21(Suppl 2):S258-S263.
8. Antonopoulou A, Giamarellos-Bourboulis EJ. Immunomodulation in sepsis: state of the art and future perspective. Immunotherapy 2011, 3:117-128. 10.2217/imt.10.82, 21174562.
9. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs 2011, 20:1555-1564. 10.1517/13543784.2011.623125, 21961576.
10. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Monoclonal antibodies. Mol Pathol 2000, 53:111-117. 10.1136/mp.53.3.111, 1186915, 10897328.
11. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986, 46:3969-3978.
12. Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986, 30:527-533. 10.1007/BF00542410, 3758140.
13. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006, 34:2271-2281. 10.1097/01.CCM.0000230385.82679.34, 16810105.
14. Newham P, Heier A, Brennan F, Ceuppens P, Growcott J. AZD9773 is a novel selective anti-TNF-α ovine polyclonal immune Fab. Clin Microbiol Infect (Suppl) 2011, abst P1438.
15. Newham P, Yates JWT, Das S, Kemp J, Ceuppens P, Brennan F, Knight R, Growcott J. Preclinical pharmacodynamics and safety profiling of AZD9773: a novel anti-TNF-α polyclonal immune ovine Fab similar to D-CytoFab. Crit Care Med 2011, 15(Suppl 1):S93. (P262).
16. R&D Systems Europe Quantikine®. Human TNF-α Immunoassay. For the quantitative determination of human tumor necrosis factor alpha (TNF-alpha) concentrations in cell culture supernates, serum, and plasma. 2011, R&D Systems Europe., http://www.rndsystems.com/pdf/dta00c.pdf
17. R&D Systems Europe Quantikine® ELISA. Human IL-6 Immunoassay. For the quantitative determination of human interleukin 6 (IL-6) concentrations in cell culture supernates, serum, and plasma. 2011, R&D Systems Europe., http://www.rndsystems.com/pdf/d6050.pdf
18. Brahms Diagnostic. Procalcitonin assays. 2011. , http://www.procalcitonin.com/default.aspx?tree = _0
19. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
20. European Medicines Agency Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. 2007, European Medicines Agency., http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
21. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16. 10.1016/j.jim.2004.06.002, 15251407.
22. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008, 48:1267-1281. 10.1016/j.jpba.2008.09.020, 18993008.
23. Yates JW, Das S, Mainwaring G, Kemp J. Population PK/PD modelling AZD9773 in patients with severe sepsis. 20th meeting of the Population Approach Group in Europe. Athens, Greece 2011, abst 2147.
24. Newham P, Snow M, Eckersley S, Davies G, Abbott M. AZD9773, a novel anti-tumor necrosis factor-a immune Fab in development for severe sepsis and septic shock: analyses of complex formation and binding sites with TNF-α. Crit Care Med 2011, 39(Suppl 12):45. (abst 183).
25. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10. 10.1016/j.ymeth.2005.01.001, 15848070.
26. BTG International Inc CroFab (Crotalidae Polyvalent Immune Fab) Prescribing Information. 2010, BTG International Inc., http://www.crofab.com/viewpdf.do?documentId=1
27. GlaxoSmithKline UK Digibind (Digoxin Immune Fab) Summary of Product Characteristics. 2010, GlaxoSmithKline UK., http://www.medicines.org.uk/EMC/medicine/12476/SPC/Digibind/